Psychotropic Medications in Pregnancy and Lactation A Risk-Benefit Review

Author Name: Dr. Sushmita Sil1, Rukmani Gharpinde2

Volume: 03/01

Country: India

DOI NO.: 08.2020-25662434 DOI Link: https://doi-ds.org/doilink/06.2025-16274424/GIJNR

Affiliation:

1. Principal, Hind School and College of Nursing, Barabanki, Uttar Pradesh, India
2. Associate Professor, Mitali Institute of Nursing, Balaghat, Madhya Pradesh, India

ABSTRACT

The use of psychotropic medications during pregnancy and lactation presents a complex clinical challenge, requiring a careful balance between maternal mental health and fetal or neonatal safety. Mental health disorders such as depression, anxiety, bipolar disorder, and schizophrenia are prevalent among women of childbearing age, and untreated illness can lead to adverse outcomes for both mother and child. However, concerns about teratogenicity, neonatal adaptation syndrome, and long-term neurodevelopmental effects often lead to hesitation in prescribing or continuing psychotropic medications during these critical periods. This review explores the classification of psychotropic drugs, their pharmacokinetics, associated risks, and the consequences of untreated maternal mental illness. It also evaluates the safety and efficacy of various medication classes, the implications of drug transfer through breast milk, and the importance of individualized clinical decision-making. The role of nurses in patient education, monitoring, and advocacy is emphasized, along with cultural and ethical considerations that influence treatment adherence. Despite growing evidence, significant gaps remain in research, particularly regarding long-term infant outcomes and the safety of newer medications. This review underscores the need for interdisciplinary collaboration and evidence-based guidelines to optimize maternal and infant health while minimizing potential risks.

Key words: Psychotropic Medication, Pregnancy and Lactation, Risk-Benefit Analysis, Maternal Mental Health, Fetal and Neonatal Outcomes.